ADVICOR TABLET (IMMEDIATE RELEASE)

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

NICOTINIC ACID; LOVASTATIN

제공처:

SEPRACOR PHARMACEUTICALS INC

ATC 코드:

C10BA01

INN (International Name):

LOVASTATIN AND NICOTINIC ACID

복용량:

500MG; 20MG

약제 형태:

TABLET (IMMEDIATE RELEASE)

구성:

NICOTINIC ACID 500MG; LOVASTATIN 20MG

관리 경로:

ORAL

패키지 단위:

3/90

처방전 유형:

Prescription

치료 영역:

HMG-COA REDUCTASE INHIBITORS

제품 요약:

Active ingredient group (AIG) number: 0251302001; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2012-08-02

제품 특성 요약

PRODUCT MONOGRAPH
PR
ADVICOR
®
extended-release niacin and lovastatin tablets
500/20 mg, 750/20 mg, 1000/20 mg and 1000/40 mg Film-Coated Tablets
Lipid Metabolism Regulator
Manufacturer:
DATE OF REVISION
:
Sepracor Pharmaceuticals, Inc.
OCTOBER 29, 2010
Mississauga, Ontario
Canada
CONTROL NO. 141231
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT
INFORMATION................................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
10
DRUG
INTERACTIONS..........................................................................................................
16
DOSAGE AND
ADMINISTRATION......................................................................................
17
OVERDOSAGE
........................................................................................................................
19
ACTION AND CLINICAL
PHARMACOLOGY....................................................................
19
STORAGE AND STABILITY
.................................................................................................
23
DOSAGE FORMS, COMPOSITION AND
PACKAGING..................................................... 23
PART II: SCIENTIFIC INFORMATION
..............................................................................
24
PHARMACEUTICAL INFORMATION
.................................................................................
24
CLINICAL
TRIALS...........................................................................................